AstraZeneca acknowledges in a contentious court battle with recipients of “defective” vaccines that their Covid vaccination MAY produce an uncommon side effect for the first time.

For the first time, AstraZeneca has acknowledged in court that a potentially fatal blood clotting side effect of the Covid vaccine exists. The extremely rare reaction is at the center of a multimillion-pound class action lawsuit filed by dozens of families claiming the ‘defective’ vaccination from the pharmaceutical giant killed or severely injured them or their loved ones.

The plaintiffs’ attorneys think that some of the cases could result in compensation of up to £20 million. The condition, which is noted as a possible side effect of the injection, was formerly known as immune thrombotic thrombocytopenia (VITT) caused by vaccination. The disclosure by AstraZeneca may result in case-by-case payouts.

The indemnification agreement that AstraZeneca made with the government during the height of the Covid pandemic to expedite the production of the vaccines while lockdowns paralyzed the nation means that taxpayers will bear the whole cost of any future settlement. It occurs only a few days after the company revealed that its first-quarter 2024 revenue exceeded £10 billion, an increase of 19%. A ‘very strong start’ to the year was reported by company officials.

 

 

Jamie Scott, an IT engineer and father of two, is one of many requesting compensation for injuries related to AstraZeneca’s vaccination. After receiving the vaccination in April 2021, he had a blood clot and a brain bleed that left him permanently impaired. Since then, he has been unable to work. His lawsuit is one of 51 that have been filed in the High Court so far, all of which seek damages estimated to be worth a combined £100 million.

AstraZeneca disputes that its latest submission amounts to a retraction of its admission in court filings that its jab may induce TTS. Under the Consumer Protection Act of 1987, AstraZeneca is being sued by attorneys on behalf of victims and their families.

The argument posits that the vaccination was “a defective product” that did not meet the expected level of safety for most consumers. AstraZeneca has refuted these allegations emphatically. But it wasn’t until April of that year that the evidence became sufficient to warrant restrictions on the jab.

Older British people who were more likely to pass away or suffer serious injuries from contracting the virus were nevertheless seen to benefit from the vaccination because it continued to protect against Covid. In the UK, around 50 million doses of the AstraZeneca injection were administered.

Unknown numbers more have been hurt and/or rendered incapacitated. Subsequent Covid vaccination launches have either reduced the dosage of the AstraZeneca injection like those produced by rival pharmaceutical behemoths Pfizer and Moderna.